 |
PDBsum entry 3qis
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/protein binding
|
PDB id
|
|
|
|
3qis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.3.1.3.36
- phosphoinositide 5-phosphatase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
1-Phosphatidyl-myo-inositol Metabolism
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + phosphate
|
 |
 |
 |
 |
 |
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)
|
+
|
H2O
|
=
|
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate)
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain A:
E.C.3.1.3.56
- inositol-polyphosphate 5-phosphatase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
1D-myo-inositol 1,4,5-trisphosphate + H2O = 1D-myo-inositol 1,4- bisphosphate + phosphate
|
|
2.
|
1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4-trisphosphate + phosphate
|
|
 |
 |
 |
 |
 |
1D-myo-inositol 1,4,5-trisphosphate
|
+
|
H2O
|
=
|
1D-myo-inositol 1,4- bisphosphate
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
1D-myo-inositol 1,3,4,5-tetrakisphosphate
|
+
|
H2O
|
=
|
1D-myo-inositol 1,3,4-trisphosphate
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chain A:
E.C.3.1.3.86
- phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4- bisphosphate) + phosphate
|
 |
 |
 |
 |
 |
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate)
|
+
|
H2O
|
=
|
1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4- bisphosphate)
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Nat Struct Biol
18:789-795
(2011)
|
|
PubMed id:
|
|
|
|
|
| |
|
Recognition of the F&H motif by the Lowe syndrome protein OCRL.
|
|
M.Pirruccello,
L.E.Swan,
E.Folta-Stogniew,
P.De Camilli.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Lowe syndrome and type 2 Dent disease are caused by defects in the inositol
5-phosphatase OCRL. Most missense mutations in the OCRL ASH-RhoGAP domain that
are found in affected individuals abolish interactions with the endocytic
adaptors APPL1 and Ses (both Ses1 and Ses2), which bind OCRL through a short
phenylalanine and histidine (F&H) motif. Using X-ray crystallography, we
have identified the F&H motif binding site on the RhoGAP domain of OCRL.
Missense mutations associated with disease affected F&H binding indirectly
by destabilizing the RhoGAP fold. By contrast, a disease-associated mutation
that does not perturb F&H binding and ASH-RhoGAP stability disrupted the
interaction of OCRL with Rab5. The F&H binding site of OCRL is conserved
even in species that do not have an identified homolog for APPL or Ses. Our
study predicts the existence of other OCRL binding partners and shows that the
perturbation of OCRL interactions has a crucial role in disease.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|